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Abstract 
Genetic testing for hereditary cancer predisposition has evolved rapidly in recent years with 
the discovery of new genes, but there is much debate over the clinical utility of testing genes 
for which there is currently limited data regarding the degree of associated cancer risk. To 
address the discrepancies that have arisen in the provision of these tests across the UK, the 
UK Cancer Genetics Group (UK-CGG), facilitated a one-day workshop with representation 
from the majority of NHS Clinical Genetics Services. Using a pre-workshop survey followed 
by focused discussion of genes without prior majority agreement for inclusion, we achieved 
consensus for panels of cancer genes with sufficient evidence for clinical utility, to be 
adopted by all NHS Genetics Services. To support consistency in the delivery of these tests 
and advice given to families across the country, we also developed management proposals 
for individuals who are found to have pathogenic mutations in these genes. However, we 
fully acknowledge that the decision regarding what test is most appropriate for an individual 
family rests with the clinician, and will depend on factors including specific phenotypic 
features and the family structure. 
 
Background 
NHS Clinical Genetics Services have in recent years taken advantage of the discovery of 
new genes and emerging evidence for associated cancer predisposition to carry out more 
extensive genetic testing via cancer gene panels, aiming to provide information and tailored 
management for more families with a hereditary cancer predisposition. However, there is 
much debate over the utility of testing genes for which there exists limited data regarding 
impact on cancer risk1, and the gradual evolution of these panels has led to discrepancies in 
the genes tested by different laboratories. This has resulted in differences between what is 
offered to patients, as well as difficulty in managing families where relatives are located in 
different parts of the country. For example, a relative may find that testing for the gene 
identified in their family is not offered in their region, or may be given different advice about 
risk management from that given to a relative with the same genetic variant. 
 
To address this, the UK Cancer Genetics Group (UK-CGG), supported by the UK Genetic 
Testing Network (UKGTN), facilitated a one-day workshop to achieve consensus for panels 
of cancer genes with clear clinical utility, to be adopted by all NHS Genetics Services. In 
addition, consensus guidelines for the management of individuals with pathogenic variants in 
these genes were subsequently developed. 
Methods 
Scope 
The workshop focused on panels of genes for breast cancer, ovarian cancer, colorectal 
cancer and polyposis. These were selected as the most commonly used panels, and also 
those with the largest discrepancies regarding inclusion of genes. 
Participants 
Invitations were sent to the Lead Cancer Clinicians at each of the 24 UK Genetics Services, 
and if unable to attend they were given the option to send a colleague in their place. All but 
two services were represented at the workshop. Also represented were Clinical Scientists 
from NHS Genetics Laboratories currently offering cancer panel tests, Genetic Counsellors 
with a specialist interest in cancer genetics, and representatives from UKGTN, UK-CGG, 
and Genomics England. 
Pre-workshop survey 
Lists of potential genes were compiled from panel tests currently on offer at both NHS and 
private laboratories. Workshop participants were surveyed for their opinions on the inclusion 
of each gene prior to the workshop, in order to focus discussion on genes where inclusion 
was most contentious. Genes were deemed to have majority agreement if >75% of 
participants said they should be included. 
Presentation of evidence for and against inclusion of genes 
Based on their survey responses, workshop participants were asked to present either for or 
against the inclusion of genes with <75% prior agreement. Those presenting in favour of 
inclusion were also asked to present management proposals for families where a pathogenic 
variant was identified (see supplementary information 1). 
Discussion groups 
Participants were divided into three groups to discuss breast cancer, epithelial ovarian 
cancer, and colorectal cancer/polyposis gene panels. Each group formulated a proposed 
panel based on the evidence presented, which was then presented to the full workshop, 
openly discussed and agreed. The focus of discussion was on the clinical utility of identifying 
pathogenic variants in each gene, but practical considerations of testing specific genes were 
also taken into account. 
Meeting report 
The agreed cancer panels were circulated to all attendees following the workshop, and were 
presented at the UK-CGG Spring Meeting 2017 for further comment. The manuscript was 
also circulated to the attendees. It should be noted that this report is a summary of the 
workshop, and therefore does not necessarily represent the opinions of individual attendees 
or Genetics Services. 
 
Results & Discussion 
Pre-workshop survey 
Responses were received from 78% (25/32) of the clinicians and clinical scientists who were 
invited to complete the survey (see supplementary information 2). The survey asked 
separate questions about inclusion of genes on breast cancer, ovarian cancer, colorectal 
cancer and polyposis panels. The results for colorectal cancer and polyposis panels 
overlapped completely, reflecting the recognised overlap in phenotypes2 and indicating that 
this should be established as a single panel. 
 
Genes with majority agreement (>75%) for each panel were as follows: 
Breast cancer: BRCA1, BRCA2, PALB2, PTEN, STK11, TP53 
Ovarian cancer: BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, RAD51C, RAD51D 
Colorectal cancer/polyposis: APC, MUTYH, SMAD4, BMPR1A, MLH1, MSH2, MSH6, 
PMS2, EPCAM (deletion of exons 8-9), POLE, POLD1, STK11 
 
Genes included or excluded following presentation of evidence and discussion 
Breast cancer panel 
It was agreed to include ATM and CHEK2, which both confer a moderately increased risk of 
breast cancer1 3, but concerns about the interpretation of results for these genes led to the 
recommendation that only truncating variants should be reported4, in addition to ATM 
c.7217T>G p.(Val2424Gly) which is recognised as conferring a higher risk of breast cancer5.  
Insufficient evidence was found for a significant risk of breast cancer associated with NBN6, 
BRIP17 or BARD16, so these were excluded from the panel. CDH1 was also excluded due to 
its relevance only in cases of lobular breast cancer, and the considerable difficulty presented 
by interpreting variants in families with no history of lobular breast cancer or diffuse gastric 
cancer8. However, testing for CDH1 should be available for relevant cases and offered 
according the current guidelines9. It was noted that the inclusion of single nucleotide 
polymorphisms (SNPs) associated with breast cancer risk10 will need to be considered in 
future, but will be more relevant to predicting risk in unaffected individuals rather than 
genetic testing of individuals with cancer11. 
 
Ovarian cancer panel 
It was agreed to include BRIP1, which confers sufficient risk of ovarian cancer such that 
prophylactic bilateral salpingo-oophorectomy is considered12. Insufficient evidence was 
found for a significant risk of ovarian cancer associated with the EPCAM deletion13, TP5314, 
and also PMS2 which originally had majority agreement in the survey, but was excluded 
when new data was taken into account15. STK11 was also excluded since mutations are 
associated only with a rare type of ovarian cancer - sex cord tumours with annular tubules - 
so testing on a gene panel primarily intended for individuals with epithelial ovarian cancer 
was not considered appropriate. For a review of genes to consider in rare non-epithelial 
ovarian neoplasms, see Foulkes et al, 201616. 
 
Colorectal cancer / polyposis panel 
Only two genes did not secure majority agreement for inclusion - GREM1 (upstream 
duplication) and NTHL1 - although the survey results suggested respondents were unsure 
about these genes rather than that they disagreed with their inclusion. Following discussion 
it was agreed that both these genes could be included, but this should be optional since the 
GREM1 upstream duplication has to date only been reported in individuals with Ashkenazi 
Jewish ancestry, and the frequency of pathogenic mutations in NTHL1 is low17. 
 
A summary of the agreed panels is given in Table 1. 
 
Table 1: Agreed panels 
Breast cancer Ovarian cancer Colorectal cancer / 
polyposis 
ATM* 
BRCA1 
BRCA2 
CHEK2** 
PALB2 
PTEN 
STK11 
TP53 
 
* truncating variants plus 
ATM c.7271T>G,  
p.( Val2424Gly) 
 
** truncating variants 
BRCA1 
BRCA2 
BRIP1 
MLH1 
MSH2 
MSH6 
RAD51C 
RAD51D 
APC 
BMPR1A 
EPCAM (del exons 8-9) 
GREM1 (upstream dup)* 
MLH1 
MSH2 
MSH6 
MUTYH 
NTHL1* 
PMS2 
POLE 
POLD1 
PTEN 
SMAD4 
STK11 
 
*optional 
 
Expected standard of analysis 
It is expected that analysis will include sequencing of the coding region and intron/exon 
boundaries of each gene, except for EPCAM and GREM1, where only the common del/dup 
need be tested for. It is expected that copy number analysis to detect exonic deletions and 
duplications from sequencing data will be possible in the near future, but in the meantime 
this analysis should be carried out separately for the key genes BRCA1, BRCA2, APC, 
MLH1, MSH2, MSH6 and PMS2. For other genes, copy number analysis can be added 
where possible, but if not included this must be made clear on the report.  
 
 
 Management proposals 
One of the key aims of this consultation was to improve consistency of service delivery 
across the UK, and it was recognised that this extends to the management of individuals 
found to have pathogenic variants, as well as which genes are included on each panel. 
Although the level of evidence for some of the included genes makes the establishment of 
firm guidelines challenging, it was agreed that pragmatic management proposals would be of 
benefit to the UK cancer genetics community. These are summarised in Table 2. 
 
Table 2 
Breast cancer genes 
Gene Breast cancer risk management References 
ATM * 
§
 
12-18 monthly mammography from 40-50 
depending on family history, then NHSBSP 
 
For c.7271T>G consider BRCA-equivalent 
Ataxia Telangiectasia in 
Children: Guidance on 
Diagnosis and Clinical 
Care18 
Protocols for the surveillance 
of women at higher risk of 
developing breast cancer, 
Public Health England 
201319 
BRCA1 As per national guidelines NICE CG16420 
BRCA2 As per national guidelines NICE CG16420 
CHEK2 + 
§
 
12-monthly mammography from 40-50, then 
NHSBSP 
 
For homozygotes consider BRCA-equivalent 
Tung et al 201621 
PALB2 
§
 
Consider BRCA-equivalent Tung et al 201621 
PTEN ++ Consider BRCA-equivalent UK-CGG Guidelines for 
management of tumour risk 
in PTEN hamartoma 
syndrome 201722 
STK11 Consider BRCA-equivalent Beggs et al, 201023 
TP53 As per national guidelines NICE CG16420 
 * The Ataxia Telangiectasia guidelines recommend 18-monthly mammography, but where 
ATM pathogenic variants are identified in the context of a significant family history of breast 
cancer it is reasonable to offer annual mammography, bringing this into line with CHEK2 
mutation carriers who have a similar risk. The guidelines do not give specific 
recommendations for the c.7271T>G variant so this is pragmatic, based on the evidence 
indicating this variant confers a much higher risk. 
+ These recommendations include mammography and/or breast MRI. Given that the risk for 
CHEK2 c.1100delC is well defined it is reasonable to offer mammography rather than MRI. 
There is much weaker evidence for other CHEK2 variants but it seems reasonable to use 
the same protocol for these until further data emerge. 
++
 These recommendations include mammography and/or breast MRI. As there is good 
evidence that the PALB2 risk is influenced by other factors such as family history it would be 
reasonable to offer BRCA-equivalent surveillance to those women ascertained via family 
history clinics (where there is a strong family history) but to consider less intense 
surveillance in those women with no significant family history (e.g. an incidental finding). 
§
 For ATM, CHEK2 and PALB2 consider using BOADICEA to guide risk management24 
 
Ovarian cancer genes 
Gene Ovarian cancer risk management References 
BRCA1 As per national guidelines NICE CG16420 
BRCA2 As per national guidelines NICE CG16420 
BRIP1 Consider RRSO at 45–50 y (and once family 
complete) 
 
Tung et al 201621 
MLH1 Consider TAH and BSO from 40 y (and once 
family complete) 
 
Vasen et al 201325, Daly et 
al 201726 
MSH2 Consider TAH and BSO from 40 y (and once 
family complete) 
Vasen et al 201325, Daly et 
al 201726 
 MSH6 Consider TAH and BSO from 40 y (and once 
family complete)  
 
Vasen et al 201325, Daly et 
al 201726 
RAD51C Consider RRSO at 45–50 y (and once family 
complete) 
 
Tung et al 201621, Daly et al 
201726 
RAD51D Consider RRSO at 45–50 y (and once family 
complete) 
 
Tung et al 201621, Daly et al 
201726 
 
 
Colorectal cancer / polyposis genes 
Syndrome Cancer risk management References 
Lynch syndrome 
 
Adenomatous 
polyposis 
syndromes 
 
Peutz Jeghers 
syndrome 
 
Juvenile polyposis 
syndrome 
 
PTEN-
hamartomatous 
tumour syndromes 
 
See International and European 
guidance as advised by InSiGHT, 
plus UK guidance on endoscopic 
colorectal surveillance issued by the 
British Society of Gastroenterology 
(due for revision).   
 
Guidance on management of Lynch 
syndrome should be interpreted in 
the light of gene, gender, age, 
previous cancer history, as shown by 
the Prospective Lynch Syndrome 
Database at http://www.lscarisk.org/  
 
The reference databases for 
interpretation of variants in MSH2, 
MLH1, MSH6, PMS2, EPCAM, APC, 
MUTYH, POLD1, POLE, and STK11, 
are provided at  
http://www.insight-
database.org/genes  
   
 
As listed under individual 
condition headings at:- 
https://www.insight-
group.org/ 
 
including:- 
 
Vasen et al 200827 
 
Cairns et al 201028 
 
Vasen et al 201325 
 
Møller et al 201715 29 
 
Conclusion 
Consensus was achieved at the workshop for genes to be included on panel tests for breast 
cancer, ovarian cancer and colorectal cancer/polyposis. Clinical entry points and testing 
criteria have not been addressed here since these are currently being developed by NHS 
England. It was recognised that when resources are limited there is a tension between 
investing in panel tests as opposed to testing a smaller number of genes with wider testing 
criteria. However, the cost of panel testing is dropping rapidly so that in the near future it will 
likely become more efficient to carry out panel testing on all patients with selective analysis 
of genes according to testing indication. From a technical point of view, this will be most 
expedient when panel tests can reliably detect all large (exonic) deletions and duplications 
as well as sequence variants. It was also recognised that access to and funding for panel 
tests currently varies across the UK, but it is hoped that one of the outcomes of this 
consultation will be improved consistency, providing centres with a standard of testing to 
work towards. However, this aim for consistency is not intended to override a clinician’s 
choice to target specific genes they consider most relevant to a particular family rather than 
offering a gene panel in every case.  
 
One factor clinicians will take into account is that testing a larger number of genes will result 
in finding more variants of uncertain significance, which carries a cost in the time spent 
interpreting and explaining the results, and can leave families with more questions than 
answers. It is essential that these are collated centrally so that a shared understanding of 
their significance can be reached more rapidly and consistent information is conveyed to 
families. It is because of the current challenges in interpreting variants of uncertain 
significance that at present we have recommended the reporting of only truncating variants 
in ATM and CHEK2. However, as these genes become better understood it will no doubt 
emerge that some missense variants also confer an increased risk of breast cancer, and it is 
possible that some could be higher penetrance alleles similar to ATM c.7271T>G. 
 
Another factor is that particularly in breast cancer families, finding a pathogenic variant in a 
moderate risk gene in the context of a high risk family history does not always aid clinical 
management, since the variant cannot be assumed to account for all of the genetic risk in 
the family. Hence offering testing to unaffected close relatives may not be informative in 
helping to advise them about their level of risk and guide decision-making around risk 
management. However, these variants can be used to identify more distantly related 
individuals (e.g. those related via intervening unaffected women) who are at moderately 
increased risk and would not have previously been eligible for additional breast screening. 
Therefore the decision about whether to offer panel testing will often depend on the family 
structure and whether there are unaffected individuals to whom the information will be 
relevant.  
 
It is important to note that this is a rapidly evolving field, and these recommendations will 
need to be revisited as further evidence emerges for inherited cancer risk. We plan to review 
the gene lists annually, and any updates will be posted on the UK-CGG website 
(http://www.ukcgg.org). In particular, the advent of routine tumour sequencing in cancer 
diagnosis and the move to whole genome sequencing and interrogation of virtual panels will 
change the contexts and capabilities of germline panel testing. As the technological barriers 
in sequencing are largely overcome, the importance of testing genes only where there is 
rigorous clinical evidence will become ever more critical. 
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